Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 21601180)

1.

Synthesis and antigenicity of BBGL-2 glycolipids of Borrelia burgdorferi, the causative agent of Lyme disease.

Pozsgay V, Kubler-Kielb J, Coxon B, Marques A, Robbins JB, Schneerson R.

Carbohydr Res. 2011 Sep 6;346(12):1551-63. doi: 10.1016/j.carres.2011.04.045. Epub 2011 May 3.

2.

A newly discovered cholesteryl galactoside from Borrelia burgdorferi.

Ben-Menachem G, Kubler-Kielb J, Coxon B, Yergey A, Schneerson R.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7913-8. Epub 2003 Jun 10.

3.

Chemoenzymatic synthesis of a glycolipid library and elucidation of the antigenic epitope for construction of a vaccine against Lyme disease.

Stübs G, Rupp B, Schumann RR, Schröder NW, Rademann J.

Chemistry. 2010 Mar 15;16(11):3536-44. doi: 10.1002/chem.200902205.

PMID:
20143357
4.

Strong IgG antibody responses to Borrelia burgdorferi glycolipids in patients with Lyme arthritis, a late manifestation of the infection.

Jones KL, Seward RJ, Ben-Menachem G, Glickstein LJ, Costello CE, Steere AC.

Clin Immunol. 2009 Jul;132(1):93-102. doi: 10.1016/j.clim.2009.03.510. Epub 2009 Apr 2.

5.

Acylated cholesteryl galactosides are specific antigens of borrelia causing lyme disease and frequently induce antibodies in late stages of disease.

Stübs G, Fingerle V, Wilske B, Göbel UB, Zähringer U, Schumann RR, Schröder NW.

J Biol Chem. 2009 May 15;284(20):13326-34. doi: 10.1074/jbc.M809575200. Epub 2009 Mar 23.

6.
7.
8.
9.
10.

Multicomponent Lyme vaccine: three is not a crowd.

Brown EL, Kim JH, Reisenbichler ES, Höök M.

Vaccine. 2005 May 25;23(28):3687-96.

PMID:
15882529
11.

Significantly improved accuracy of diagnosis of early Lyme disease by peptide enzyme-linked immunosorbent assay based on the borreliacidal antibody epitope of Borrelia burgdorferi OspC.

Jobe DA, Lovrich SD, Asp KE, Mathiason MA, Albrecht SE, Schell RF, Callister SM.

Clin Vaccine Immunol. 2008 Jun;15(6):981-5. doi: 10.1128/CVI.00079-08. Epub 2008 Apr 16.

12.
13.

Structural analysis of glycolipids from Borrelia burgdorferi.

Hossain H, Wellensiek HJ, Geyer R, Lochnit G.

Biochimie. 2001 Jul;83(7):683-92.

PMID:
11522398
14.

Immunization with a Borrelia burgdorferi BB0172-derived peptide protects mice against lyme disease.

Small CM, Ajithdoss DK, Rodrigues Hoffmann A, Mwangi W, Esteve-Gassent MD.

PLoS One. 2014 Feb 5;9(2):e88245. doi: 10.1371/journal.pone.0088245. eCollection 2014.

15.
16.

Structural analysis of an outer surface protein from the Lyme disease spirochete, Borrelia burgdorferi, using circular dichroism and fluorescence spectroscopy.

France LL, Kieleczawa J, Dunn JJ, Hind G, Sutherland JC.

Biochim Biophys Acta. 1992 Mar 27;1120(1):59-68.

PMID:
1554741
17.

Reductions in human Lyme disease risk due to the effects of oral vaccination on tick-to-mouse and mouse-to-tick transmission.

Voordouw MJ, Tupper H, Önder Ö, Devevey G, Graves CJ, Kemps BD, Brisson D.

Vector Borne Zoonotic Dis. 2013 Apr;13(4):203-14. doi: 10.1089/vbz.2012.1003. Epub 2013 Feb 21.

18.

Artificial-infection protocols allow immunodetection of novel Borrelia burgdorferi antigens suitable as vaccine candidates against Lyme disease.

Wallich R, Jahraus O, Stehle T, Tran TT, Brenner C, Hofmann H, Gern L, Simon MM.

Eur J Immunol. 2003 Mar;33(3):708-19.

PMID:
12616491
19.

Identification of an immunoreactive non-proteinaleous component in Borrelia burgdorferi.

Eiffert H, Lotter H, Jarecki-Khan K, Thomssen R.

Med Microbiol Immunol. 1991;180(5):229-37.

PMID:
1722277
20.

Specific immune response to a synthetic peptide derived from outer surface protein C of Borrelia burgdorferi predicts protective borreliacidal antibodies.

Ikushima M, Matsui K, Yamada F, Kawahashi S, Nishikawa SK.

FEMS Immunol Med Microbiol. 2000 Sep;29(1):15-21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk